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Here we show that cellular retinoic acid binding protein-II (CRABP-II) can be speciﬁcally degraded
by a novel compound, SNIPER-4, consisting of ()-N-[(2S,3R)-3-amino-2-hydroxy-4-phenyl-
butyryl]-L-leucine methyl ester and all-trans retinoic acid that are ligands for cellular inhibitor of
apoptosis protein 1 (cIAP1) and CRABP-II, respectively. Mechanistic analysis revealed that SNIPER-
4 induces cIAP1-mediated ubiquitylation of CRABP-II, resulting in the proteasomal degradation.
The protein knockdown strategy employing the structure of SNIPER-4 could be applicable to other
target proteins.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The ubiquitin–proteasome system (UPS) plays a crucial role in
selective degradation of proteins, which is involved in the regula-
tion of cell cycle, proliferation, differentiation and cell death [1–
3]. In the UPS, the target protein is poly-ubiquitylated by the
sequential action of ubiquitin-activating enzyme (E1), ubiquitin-
conjugating enzyme (E2) and ubiquitin-ligase (E3), where E3
determines the speciﬁcity for the target protein in many cases.
The poly-ubiquitylated proteins are degraded by proteasome. Inap-
propriate regulation of the UPS results in an accumulation or
depletion of certain proteins, which results in a variety of diseases
such as cancer, cachexia, neurodegenerative disorders and malfor-
mation [4–8]. To reduce a pathogenic protein in cells, it is useful to
take advantage of the UPS since it is a highly speciﬁc system tochemical Societies. Published by E
sis protein 1; MeBS, ()-N-
ine methyl ester; ATRA, all-
ng protein
emistry and Molecular Biol-
amiyoga, Setagaya-ku, Tokyotarget a certain protein for degradation, and the degradation occurs
very quickly. However, few studies have been reported so far on
the speciﬁc degradation of target proteins utilizing the UPS [9].
We previously reported that a class of small molecules, repre-
sented by ()-N-[(2S,3R)-3-amino-2-hydroxy-4-phenyl-butyryl]-
L-leucine methyl ester (MeBS), destabilize cellular inhibitor of
apoptosis protein 1 (cIAP1), a ubiquitin-ligase (E3) belonging to
IAP (inhibitor of apoptosis protein) family [10–12], and sensitize
cancer cells to apoptosis induced by anti-cancer drugs and death
receptor ligation [13–16]. MeBS directly interacts with cIAP1 at
its BIR3 domain and induces auto-ubiquitylation of cIAP1 depend-
ing on its RING domain, resulting in the proteasomal degradation
of cIAP1. Structure–activity relationship study indicated that ana-
logs with a carboxyl-ester reduce the amount of cIAP1 even though
the methyl group is substituted to other residues, and other mod-
iﬁcations of MeBS seriously affected the activity [13]. Based on
these observations, we hypothesized that the methyl group can
be substituted to a ligand for a target protein without ablating
the ubiquitin ligase activity of cIAP1. The hybrid molecule consist-
ing of MeBS and the ligand would be able to cross-link cIAP1 and
the target protein, to induce ubiquitylation and proteasomal degra-
dation of the target protein. As a proof-of-concept study, we de-
signed and synthesized a series of hybrid compounds consisting
of MeBS and all-trans retinoic acid (ATRA), and found that theylsevier B.V. All rights reserved.
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Fig. 1. Structure and protein knockdown activity of SNIPERs. (A) Structures of MeBS (top), SNIPER-2 (middle) and SNIPER-4 (bottom). (B) Reduction of endogenous CRABP-II
and cIAP1 by SNIPER-2. (C) SNIPER-4 reduces endogenous CRABP-II but not cIAP1. (D) Inhibition of the SNIPER-mediated protein knockdown by a proteasome inhibitor,
MG132. Human primary ﬁbroblasts (B), HT1080 (C) or HT1080 cells expressing FLAG-CRABP-II (D) were incubated with 10 lMof indicated compounds for 6 h. Cells were pre-
treated with 10 lM of MG132 for 30 min in (D). Shown are immunoblots of cell lysates stained with indicated antibodies.
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protein [17]. Thus, selective degradation of target protein (protein
knockdown) can be attained by the hybrid molecules that cross-
link the target protein and cIAP1.
The hybrid molecule we have developed previously [17], which
we named SNIPER (Speciﬁc and Non-genetic IAP-dependent Pro-
tein ERaser)-2 in this study, however, has two major downsides
that would be unfavorable for protein knockdown: (1) SNIPER-2
causes a simultaneous degradation of cIAP1 with the target protein
CRABP-II, which may make the protein knockdown unsustainable,
and (2) SNIPER-2 contains an ester-bond which is vulnerable to
hydrolysis. To overcome these issues, we here developed SNIPER-
4, in which the ester-bond is substituted to amide-bond, and found
that the SNIPER-4 induces speciﬁc and sustained degradation of
CRABP-II without inducing cIAP1 degradation. We also investi-
gated biochemical mechanisms by which SNIPERs target CRABP-
II for degradation, and demonstrate that SNIPERs induce the ubiq-
uitylation of CRABP-II, which is mediated by cIAP1 but not by XIAP.
2. Materials and methods
2.1. Reagents and plasmids
MeBS was kindly provided by Nippon Kayaku Co. Ltd. (Tokyo,
Japan). SNIPER-2 was synthesized as described previously [17].
The synthesis and structural analysis of SNIPER-4 would be re-
ported elsewhere (Itoh et al., manuscript in preparation). cDNA
encoding human CRABP-II were ampliﬁed by PCR from JHH-5
cDNA library and cloned into a p3xFLAG-CMV-10 expression
vector (SIGMA). The correct DNA sequence was conﬁrmed. Thefollowing reagents were purchased from indicated supplier: M2
anti-FLAG mouse monoclonal antibody, M2 anti-FLAG agarose-
conjugated antibody, mouse anti-b-actin antibody (SIGMA);
Fugene HD, anti-HA rat monoclonal antibody (Roche); CRABP-II
antibody (Abcam); anti-human cIAP1 goat polyclonal antibody
(R&D systems); anti-human XIAP mouse monoclonal antibody
(MBL); Lipofectamine RNAi MAX transfection reagent, Stealth Se-
lect RNAi (Invitrogen). The target sequences for cIAP1 and XIAP
RNAi were as follows: cIAP1-#1 (50-TCTAGAGCAGTTGAAGA-
CATCTCTT-30); cIAP1-#2 (50-GGAAATGCTGCGGCCAACATCTTCA-
30); XIAP-#1 (50-ACACTGGCACGAGCAGGGTTTCTTT-30); XIAP-#2
(50-CCAGAATGGTCAGTACAAAGTTGAA-30).
2.2. Cell culture, transfection and treatment with compounds
Human ﬁbrosarcoma HT1080 were maintained in RPMI 1640
medium containing 10% fetal bovine serum and 100 lg/ml of kana-
mycin. Transient transfections were carried out using Fugene HD
according to the manufacturer’s instructions. siRNA transfections
were carried out by reverse transfection method with Lipofect-
amine RNAi MAX according to the manufacturer’s instructions. In
brief, 60 pmol siRNA and 3 ll of Lipofectamine RNAi MAX were
incubated in 200 ll Opti-MEM medium for 20 min at room tem-
perature in 12-well plates, and then 1 ml of cell suspension
(1.5  105 cells) was added to the siRNA–RNAi MAX complex.
HT1080 cells constitutively expressing FLAG-CRABP-II were gener-
ated and maintained in RPMI 1640 medium containing 10% fetal
bovine serum and 100 lg/ml of kanamycin and 500 lg/ml of
Geneticin (G418). The cells were treated with 10 lM SNIPERs or
vehicle (DMSO) for 6 h unless otherwise indicated, and lysed in
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Fig. 2. (A and B) Time-course and (C) dose-dependent response of CRABP-II degradation induced by SNIPERs. HT1080 cells constitutively expressing FLAG-CRABP-II were
incubated with 10 lM compounds for indicated times (A and B), or 0.3, 1 or 3 lM of compounds for 6 h (C, from the left of black triangle). Cell lysates were Western blotted
with indicated antibodies.
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boiled for 10 min. Protein concentration was measured by BCA
method (Pierce) and the equal amount of protein lysate was sepa-
rated by SDS–PAGE, transferred to Hybond-P (GE Healthcare)
membrane and Western blotted using appropriate antibody. Pro-
tein signals were detected using SuperSignal West Femto Maxi-
mum Sensitivity Substrate (Thermo scientiﬁc) or ECL™ Western
Blotting Detection Reagents (GE Healthcare).
2.3. Ubiquitylation of CRABP-II
HA–ubiquitin was transiently transfected in HT1080 cells con-
stitutively expressing FLAG-CRABP-II. Cells were lysed in lysis buf-
fer and boiled, and the lysates were diluted 10 times with 0.1 M
Tris–HCl. CRABP-II was immunoprecipitated with anti-FLAG aga-
rose-conjugated beads. The immunoprecipitates were extensively
washed with diluted lysis buffer, and analyzed by Western blotting
using anti-HA antibody.
3. Results and discussion
The structures of MeBS (top), SNIPER-2 (middle) and SNIPER-
4 (bottom) are shown in Fig. 1A. These SNIPERs are hybrid mol-
ecules consisting of bestatin moiety and ATRA connected by an
ester-bond (SNIPER-2) or an amide-bond (SNIPER-4) spacer. SNI-
PER-2 induces the degradation of endogenous CRABP-II and
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Fig. 4. Silencing of cIAP1 attenuates the SNIPER-dependent CRABP-II protein
degradation. In HT1080 cells expressing FLAG-CRABP-II, the endogenous cIAP1
and XIAP were knocked down by two different siRNAs (#1 or #2) against each
protein for 48 h (A). cIAP1, XIAP or both were knocked down by siRNAs (cIAP1-#1,
XIAP-#2) (B). Cells were incubated with 10 lM compounds for 6 h. Shown are
immunoblots of cell lysates stained with indicated antibodies.
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(Fig. 1B) [17]. To develop a novel SNIPER that reduces CRABP-II
but not cIAP1, we designed SNIPER-4 in which the ester-bond
is substituted to amide-bond, because our previous study indi-
cated that bestatin methyl amide could bind to cIAP1 without
reducing it [13]. Fig. 1C shows that the SNIPER-4 reduced the le-
vel of CRABP-II but not cIAP1 in HT1080 cells as we speculated.
SNIPER-2 reduced both the CRABP-II and cIAP1, while MeBS re-
duced cIAP1 speciﬁcally. Likewise, in HT1080 cells expressing
FLAG-tagged CRABP-II, SNIPER-4 reduced FLAG-CRABP-II but
not cIAP1. The combined use of MeBS and ATRA did not induce
the degradation of CRABP-II (Supplementary Fig. 1). In addition,
the reduction of CRABP-II by SNIPER-4 and SNIPER-2, and that
of cIAP1 by MeBS and SNIPER-2, were all abrogated by a protea-
some inhibitor, MG132 (Fig. 1D). These results indicate that SNI-
PER-2 induces proteasomal degradation of CRABP-II and cIAP1
while SNIPER-4 degrades CRABP-II speciﬁcally, and that the link-
ing MeBS and ATRA in one molecule is required for the CRABP-II
degradation.
Then, we evaluated the effect of SNIPERs on the target protein
degradation, examining the reaction time-course and the treat-
ment dose. As shown in Fig. 2A, SNIPER-2 and -4 reduce the
CRABP-II at 1 h, then kept suppressing the CRABP-II expression
over 20 h. On a longer time scale, the expression levels of CRABP-
II at 24 or 48 h were lower in the cells treated with SNIPER-4 than
with SNIPER-2 (Fig. 2B). This may be due to the maintenance of
cIAP1 level in the SNIPER-4-treated cells (Fig. 2A and B), and/or
the chemical stability of SNIPER-4 compared with SNIPER-2 since
ester-bond is more easily hydrolyzed than amide-bond. We also
tested the dose–response of SNIPERs on CRABP-II degradation.
The CRABP-II was effectively reduced by over 3 lM and subtlyaffected by 0.3 lM or 1 lM of SNIPER-4 (Fig. 2C and Supplemen-
tary Fig. 2).
Next, we examined whether the SNIPERs induce the ubiquityla-
tion of CRABP-II as we assumed. Lysates from the cells expressing
FLAG-tagged CRABP-II and HA-tagged ubiquitin were immunopre-
cipitated with anti-FLAG (CRABP-II) and the immunoprecipitates
were analyzed by Western blot with anti-HA (ubiquitin) to detect
the ubiquitylated CRABP-II. Smear protein bands that migrate
slowly in the gels increased by SNIPER-2 and SNIPER-4 (Fig. 3),
which indicates the poly-ubiquitylation of CRABP-II. We further
examined whether cIAP1 is the ubiquitin ligase responsible for
the degradation of CRABP-II in the SNIPER-treated cells. Silencing
cIAP1 expression by siRNAs signiﬁcantly suppressed the SNIPER-
mediated CRBAP-II degradation, whereas silencing XIAP, a close
family member of cIAP1, did not (Fig. 4A and B). Expression of
cIAP2, another close family member, is hardly detected in
HT1080 cells (data not shown). These results indicate that cIAP1
is the primary ubiquitin ligase for CRABP-II.
Fig. 5 shows the schema of the protein knockdown by MeBS,
SNIPER-2 and SNIPER-4. MeBS interacts with BIR3 domain of cIAP1
to induce auto-ubiquitylation mediated by its RING domain for
proteasomal degradation (Fig. 5, top). SNIPER-2 with ester-bond
cross-links cIAP1 and CRABP-II, and induces ubiquitylation of both
proteins, resulting in the degradation of cIAP1 and CRABP-II by
proteasome (Fig. 5, middle). SNIPER-4 with amide-bond also
cross-links cIAP1 and CRABP-II, but it speciﬁcally induces proteaso-
mal degradation of CRABP-II but not cIAP1 (Fig. 5, bottom). Thus,
the amide-type SNIPER-4 would be more useful than the ester-type
SNIPER-2 for protein knockdown in terms of the speciﬁcity and
prolonging the duration of the degradation process.
The reason why SNIPER-4 does not degrade cIAP1 is not fully
understood. We previously reported that bestatin-methyl ester
(MeBS) induced proteasomal degradation of cIAP1, whereas best-
atin-methyl amide (BE-04) did not (13). Therefore, we hypothe-
size that BE-04 and SNIPER-4 with amide-bond would not
induce auto-ubiquitylation of cIAP1, or if any it is not enough
for efﬁcient proteasomal degradation. Probably, the robustness
and/or kinetics of the auto-ubiquitylation would be much lower
than that induced by MeBS and SNIPER-2 with ester-bond, and
therefore, de-ubiquitylation of cIAP1 quickly occurs to prevent
degradation.
To study physiological functions of certain proteins, genetic
knockdown by RNA interference or genetic knockout by gene tar-
geting was commonly applied for suppressing the expression.
Comparing with such genetic methods, the protein knockdown
by SNIPERs has several advantages: (i) SNIPERs are small molecules
and easily delivered into cells, which is especially advantageous for
medical application in future. (ii) The degradation of the target
protein begins soon after the addition of SNIPERs, and therefore
the protein knockdown is attained in several hours. We suppose
that the protein knockdown by SNIPERs could be a complementary
technology to RNA interference, and if combined it may be possible
to downregulate a target protein more rapidly and robustly. This is
especially the case for a long-lived protein that is insufﬁciently
downregulated by RNA interference alone.
The protein knockdown by SNIPERs depends on cIAP1-mediated
ubiquitylation of the target protein. The cIAP1 is ubiquitously ex-
pressed in a variety of tissues and cells [18], indicating that the
protein knockdown by SNIPERs would be attained in most tissues
and cells expressing cIAP1. Since cIAP1 is involved in NFjB signal-
ing in some cells, the effect of SNIPERs on normal cell function
should be carefully investigated. Structurally, SNIPERs could target
other proteins for degradation if ATRA is substituted to ligands for
other target proteins. We propose the amide-type SNIPER could be
applicable to downregulate pathogenic proteins for therapeutic
purposes.
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